PRESENTLY, OVER 40 PLAYERS, BASED IN DIFFERENT REGIONS OF THE WORLD CLAIM TO OFFER BIOASSAY SERVICES FOR CELL

During our research, we were able to capture more than 40 players, which claims to offer bioassay services related for cell and gene therapies.
Report Link -https://www.rootsanalysis....

Amongst the total players offering bioassay services for cell and gene therapies, most of the players engaged in this domain were established before 1995. Of these, nine are headquartered in North America, while eight are based in Europe. Further, the industry witnessed the establishment of nine players, post 2010. Of these, five are based in North America, three in Europe and one in the Asia-Pacific region. In addition to this, all of the bioassay service providers (100%) are offering pre-developed assay. This is followed by 89% players that offer customized assays for cell and gene therapies.

For Customize report -https://www.rootsanalysis....

Further, as can be observed from the figure, 75% service providers claim to have the required capabilities to offer services related to immunoassay. Besides this, we came across two companies which offer all the aforementioned bioanalytical services. Examples of such players include (in alphabetical order), BioAgilytix and PPD Laboratories. It is worth highlighting that, of the total companies offering bioassay services, close to 60% offer services both in vitro as well as in vivo type of bioassay for cell and gene therapies.

As the figure represents, majority are mid-sized players (48%). Of these, most (25%) of companies have been established between 2000 to 2010. This is followed by the large firms (36%), of which companies established before 1945 are (in reverse chronological order of year of establishment) BD Biosciences (1897), Lonza (1897), SGS (1878), Siemens Healthineers (1847) and Merck KGaA (1668).

For free Insights - https://www.rootsanalysis....

Majority of the companies (89%) offer bioassay services for cell therapies, followed by 86% companies offering bioassay services for gene therapies. Further, immunoassay was found to be the most common bioanalytical service, provided by 75% companies. This is followed by potency assay and ELISA offered by 66% bioassay service providers.

For additional details, please visit – https://www.rootsanalysis....

You may also be interested in the following titles:
1. Global T-Cell Therapies Market (5th Edition): Industry Trends and Global Forecasts, 2021-2030
2. CAR-T Cell Therapies Market (3rd Edition): Industry Trends and Global Forecasts, 2021-2030
3. TCR-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
4. Cell and Gene Therapy CROs Market: Industry Trends and Global Forecasts (2nd Edition), 2021-2030
5. Gene Therapy Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com

Contact Details
Ben Johnson
+1 (415) 800 3415
ben.johnsonrootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis....
LinkedIn: https://in.linkedin.com/co...
Twitter: https://twitter.com/RootsA...
Medium: https://medium.com/RootsA...
Pinterest: https://in.pinterest.com/R...
Quora: https://rootsanalysisinsig...

Biopharmaceutical Contract Biomanufacturing Market, (4th Edition), 2020-2030
Owing to the complexities associated with the production of biologics, biopharmaceutical developers are likely to continue relying on contract service providers for various aspects of their respective product development programs
London
Roots Analysis has announced the addition of the “Biopharmaceutical Contract Biomanufacturing Market, (4th Edition), 2020-2030” report to its list of offerings.
Given the rising popularity of biologics and the 8,000+ such product candidates under clinical investigation, the opportunity for contract manufacturing service providers engaged in this domain, is high and anticipated to persist in the mid-long term, as well. In fact, since 2000, over 120 new CMOs have been established, offering a variety of cost-efficient manufacturing services and solutions to biologic developers.
To order this 780+ page report, which features 300+ figures and 270+ tables, please visit this - https://www.rootsanalysis....

Key Market Insights
Presently, 225 CMOs, possessing over 380 manufacturing facilities, claim to offer manufacturing services for biopharmaceutical products
The manufacturing services market for biopharmaceuticals is highly fragmented, featuring a mix of small, mid-sized, large and very large players. It is worth mentioning that more than 60% of CMOs mentioned in the report, have the necessary capabilities to manufacture biologics across all scales of operation.

More than 65% of service providers offer manufacturing services for recombinant proteins and peptides
Close to 58% of CMOs claim to have the required capabilities to offer antibody manufacturing services. It is worth mentioning that a number of biologics manufacturers are presently offering services related to the niche and emerging classes of biologics.

Over 620 partnerships were established in this domain, during the period 2015-2020
Majority of the deals (~24%) recorded in the report, were established in 2020, primarily driven by the investigational biologic drugs against COVID-19. Further, a large number (~35%) of the partnerships were observed to be focused on the manufacturing of biologics, followed by product development and manufacturing agreements (22%).

Currently, the installed biopharmaceutical contract manufacturing capacity is estimated to be ~3.9 million liters, which is gradually being expanded
In order to meet the growing demand for biologics, 177 expansion projects were undertaken by CMOs between 2016 and 2020 Of the aforementioned initiatives, more than 40% were focused on the establishment of new facilities, followed by the expansion of existing manufacturing facilities (24%).

North America and Europe are anticipated to capture 75% share (in terms of service revenues) of the market, by 2030
At present, close to 90% of the total revenues are generated from projects involving commercialized biologic products, and this trend is unlikely to change significantly in the short to mid-term. Further, it is worth mentioning that the contract biomanufacturing market for biologics in the Middle East and North Africa is anticipated to grow at a relatively faster rate (13.6%), followed by the Asia-Pacific market (11.2%).

To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis....

Key Questions Answered
 Who are the leading players offering contract manufacturing services for biologics?
 What percentage of the manufacturing operations for biopharmaceutical are presently outsourced?
 What factors should be taken into consideration while deciding whether the manufacturing operations for biologics should be kept in-house or outsourced?
 What is the current, installed capacity for contract manufacturing for biopharmaceuticals?
 What is the current, global demand for biologics and how is it likely to evolve in the foreseen future?
 What are the key (geographical) manufacturing hubs for biologics?
 What kind of partnership models are commonly adopted by stakeholders engaged in this domain?
 What are the different biopharmaceuticals focused initiatives undertaken by big pharma players in the recent past?
 How is the current and future market opportunity likely to be distributed across key market segments?

The USD 34.2 billion (by 2030) financial opportunity within the biopharmaceutical contract manufacturing market has been analyzed across the following segments:
 Commonly outsourced business operations
 API
 FDF

 Types of Expression Systems Used
 Mammalian
 Microbial
 Others

 Scale of Operation
 Preclinical / Clinical
 Commercial

 Company Size
 Small
 Mid-sized
 Large / Very Large

 Types of Biologics Manufactured
 Antibody Therapeutics
 Vaccines
 Cell Therapies
 Other Biologics

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific
 Latin America
 Middle East and North Africa

The report includes profiles of key players (listed below) each profile features an overview of the company, information related to its biologics focused service portfolio, manufacturing facilities, recent developments, and an informed future outlook.
 AGC Biologics
 Boehringer Ingelheim
 Catalent
 Cytiva (GE Healthcare)
 FUJIFILM Diosynth Biotechnologies
 KBI Biopharma
 Kemwell Biopharma
 Lonza
 Luina Bio
 Novasep
 Olon
 Patheon
 Piramal Pharma Solutions
 Takara Bio
 WuXi AppTec (WuXi Biologics)

For additional details, please visit
https://www.rootsanalysis.... email salesrootsanalysis.com

You may also be interested in the following titles:
1. Vaccine Contract Manufacturing Market (3rd Edition), 2021-2030
2. ADC Contract Manufacturing Market (4th Edi

Antibody Contract Manufacturing Market, 2020-2030 by Roots Analysis

With over 100 therapeutic monoclonal antibodies and antibody-based products in the market, the demand for developing and manufacturing of such products is anticipated to increase beyond the capabilities of innovator companies alone

Roots Analysis has announced the addition of the “Antibody Contract Manufacturing Market, 2020-2030” report to its list of offerings.

Although biopharmaceuticals offer significant profit margins and have been proven to be effective in treating a myriad of diseases, they are generally associated with high costs of development and complex manufacturing protocols; this is true for antibody-based products as well. Presently, there are a number of companies that claim to offer end-to-end solutions, ranging from antibody development to commercial production. Further, prevalent trends suggest that sponsor companies are likely to continue relying on contract service providers for various aspects of antibody-based product development and manufacturing.

To order this 285+ page report, which features 100+ figures and 110+ tables, please visit this - https://www.rootsanalysis....

Key Market Insights

Over 100 CMOs presently claim to offer manufacturing services for antibodies
The Antibody Contract manufacturing market is currently dominated by the presence of small and mid-sized companies, which represent 70% of the industry stakeholders. It is also worth highlighting that more than 55% of CMOs claim to have the capabilities to manufacture antibodies across all scales of operation (preclinical, clinical and commercial).

More than 90% service providers are focused on the production of monoclonal antibodies
However, players based in Asia are now increasingly focusing on the development of bispecific antibodies for therapeutic use. It worth highlighting that close to 20% of the CMOs engaged in this domain claim to offer manufacturing services for both bispecific antibodies and antibody fragments.

Europe has emerged as a key manufacturing hub for antibody-based products
More than 120 manufacturing facilities have been established by various players, worldwide; of these, 40% are in Europe. Additionally, 40% of the total installed capacity is in Europe, followed by Asia. Some of the prominent regions in Asia include (in decreasing order of number of manufacturing facilities) China, South Korea, India, Japan and Taiwan.

More than 90 partnership agreements have been inked between 2013 and 2019
Majority of these agreements were focused on manufacturing of various types of antibodies. Other popular types of collaboration models include process development and manufacturing agreements (22%), product development and manufacturing agreements (10%) and licensing agreements (7%).

Multiple expansion initiatives were undertaken by CMOs between 2017 and 2019
More than 50% of such initiatives were reported to be focused on the expansion of manufacturing facilities, followed by building new facilities (38%). It is worth noting that close to 50% of the total number of expansion initiatives were undertaken in Europe, of which, 25% were in the UK.

Demand for therapeutic antibodies is anticipated to grow at a CAGR of 10%, during 2020-2025
Given the fact that there are a number of antibody-based products in the market, the commercial demand for antibodies is significantly higher than the clinical demand. Across the three major global regions, North America represent over half of the overall global manufacturing demand for antibodies.

North America and Europe are anticipated to capture over 70% of the market share by 2030
However, the market in the Asia is anticipated to grow at a relatively faster rate. Further, presently, more than 90% of the antibodies are being developed using mammalian expression systems, and this trend is unlikely to change significantly in short to mid-term.

To request a sample copy / brochure of this report, please visit this- https://www.rootsanalysis....

Key Questions Answered
 Who are the leading CMOs engaged in the production of antibody-based therapeutics?
 What kind of partnership models are commonly adopted by stakeholders in this industry?
 What is the annual clinical and commercial demand for antibody-based products?
 What is the current installed capacity for manufacturing of antibodies?
 What are the various expansion initiatives undertaken by antibody CMOs?
 How is the current and future market opportunity likely to be distributed across key market segments?

The USD 17 billion (by 2030) financial opportunity within the antibody contract manufacturing market has been analyzed across the following segments:
 Type of Antibodies
 Monoclonal Antibodies
 Bispecific Antibodies
 ADCs
 Others

 Company Size
 Small
 Mid-sized
 Large / Very Large

 Scale of Operation
 Preclinical / Clinical
 Commercial

 Type of expression system used
 Mammalian
 Microbial

 Key geographical regions
 North America
 Europe
 Asia and RoW

The report features inputs from eminent industry stakeholders, according to whom antibody therapeutics developers are increasingly outsourcing their manufacturing operations owing to complex nature of the overall process, as well as the high investments associated with setting-up in-house expertise. The report includes detailed transcripts of discussions held with the following experts:
 Dietmar Katinger (Chief Executive Officer, Polymun Scientific)
 David C Cunningham (Director, Corporate Development, Goodwin Biotechnology)
 Claire Otjes (Marketing Manager, Batavia Biosciences)

The research covers profiles of key players that offer manufacturing services for antibodies, featuring a company overview, information on their respective service portfolios, manufacturing facilities and ca

Polycystic Ovary Syndrome 2021-2031 by Roots Analysis

Owing to the complexities associated with the production of biologics, biopharmaceutical developers are likely to continue relying on contract service providers for various aspects of their respective product development programs
London
Roots Analysis has announced the addition of the “Biopharmaceutical Contract Biomanufacturing Market, (4th Edition), 2020-2030” report to its list of offerings.
Given the rising popularity of biologics and the 8,000+ such product candidates under clinical investigation, the opportunity for contract manufacturing service providers engaged in this domain, is high and anticipated to persist in the mid-long term, as well. In fact, since 2000, over 120 new CMOs have been established, offering a variety of cost-efficient manufacturing services and solutions to biologic developers.
To order this 780+ page report, which features 300+ figures and 270+ tables, please visit this - https://www.rootsanalysis....

Key Market Insights
Presently, 225 CMOs, possessing over 380 manufacturing facilities, claim to offer manufacturing services for biopharmaceutical products
The manufacturing services market for biopharmaceuticals is highly fragmented, featuring a mix of small, mid-sized, large and very large players. It is worth mentioning that more than 60% of CMOs mentioned in the report, have the necessary capabilities to manufacture biologics across all scales of operation.

More than 65% of service providers offer manufacturing services for recombinant proteins and peptides
Close to 58% of CMOs claim to have the required capabilities to offer antibody manufacturing services. It is worth mentioning that a number of biologics manufacturers are presently offering services related to the niche and emerging classes of biologics.

Over 620 partnerships were established in this domain, during the period 2015-2020
Majority of the deals (~24%) recorded in the report, were established in 2020, primarily driven by the investigational biologic drugs against COVID-19. Further, a large number (~35%) of the partnerships were observed to be focused on the manufacturing of biologics, followed by product development and manufacturing agreements (22%).

Currently, the installed biopharmaceutical contract manufacturing capacity is estimated to be ~3.9 million liters, which is gradually being expanded
In order to meet the growing demand for biologics, 177 expansion projects were undertaken by CMOs between 2016 and 2020 Of the aforementioned initiatives, more than 40% were focused on the establishment of new facilities, followed by the expansion of existing manufacturing facilities (24%).

North America and Europe are anticipated to capture 75% share (in terms of service revenues) of the market, by 2030
At present, close to 90% of the total revenues are generated from projects involving commercialized biologic products, and this trend is unlikely to change significantly in the short to mid-term. Further, it is worth mentioning that the contract biomanufacturing market for biologics in the Middle East and North Africa is anticipated to grow at a relatively faster rate (13.6%), followed by the Asia-Pacific market (11.2%).

To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis....

The USD 34.2 billion (by 2030) financial opportunity within the biopharmaceutical contract manufacturing market has been analyzed across the following segments:
 Commonly outsourced business operations
 API
 FDF

 Types of Expression Systems Used
 Mammalian
 Microbial
 Others

 Scale of Operation
 Preclinical / Clinical
 Commercial

 Company Size
 Small
 Mid-sized
 Large / Very Large

 Types of Biologics Manufactured
 Antibody Therapeutics
 Vaccines
 Cell Therapies
 Other Biologics

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific
 Latin America
 Middle East and North Africa

The report includes profiles of key players (listed below) each profile features an overview of the company, information related to its biologics focused service portfolio, manufacturing facilities, recent developments, and an informed future outlook.
 AGC Biologics
 Boehringer Ingelheim
 Catalent
 Cytiva (GE Healthcare)
 FUJIFILM Diosynth Biotechnologies
 KBI Biopharma
 Kemwell Biopharma
 Lonza
 Luina Bio
 Novasep
 Olon
 Patheon
 Piramal Pharma Solutions
 Takara Bio
 WuXi AppTec (WuXi Biologics)

For additional details, please visit
https://www.rootsanalysis.... email salesrootsanalysis.com

You may also be interested in the following titles:
1. Vaccine Contract Manufacturing Market (3rd Edition), 2021-2030
2. ADC Contract Manufacturing Market (4th Edition), 2020-2030
3. Microbial Contract Manufacturing Market, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com

Contact Details
Ben Johnson
+1 (415) 800 3415
ben.johnsonrootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis....
LinkedIn: https://in.linkedin.com/co...
Twitter: https://twitter.com/RootsA...
Medium: https://medium.com/RootsA...
Pinterest: https://in.pinterest.com/R...
Quora: https://rootsanalysisinsig...

Biopharmaceutical Contract Biomanufacturing Market, (4th Edition), 2020-2030

Owing to the complexities associated with the production of biologics, biopharmaceutical developers are likely to continue relying on contract service providers for various aspects of their respective product development programs
London
Roots Analysis has announced the addition of the “Biopharmaceutical Contract Biomanufacturing Market, (4th Edition), 2020-2030” report to its list of offerings.
Given the rising popularity of biologics and the 8,000+ such product candidates under clinical investigation, the opportunity for contract manufacturing service providers engaged in this domain, is high and anticipated to persist in the mid-long term, as well. In fact, since 2000, over 120 new CMOs have been established, offering a variety of cost-efficient manufacturing services and solutions to biologic developers.
To order this 780+ page report, which features 300+ figures and 270+ tables, please visit this - https://www.rootsanalysis....

Key Market Insights
Presently, 225 CMOs, possessing over 380 manufacturing facilities, claim to offer manufacturing services for biopharmaceutical products
The manufacturing services market for biopharmaceuticals is highly fragmented, featuring a mix of small, mid-sized, large and very large players. It is worth mentioning that more than 60% of CMOs mentioned in the report, have the necessary capabilities to manufacture biologics across all scales of operation.

More than 65% of service providers offer manufacturing services for recombinant proteins and peptides
Close to 58% of CMOs claim to have the required capabilities to offer antibody manufacturing services. It is worth mentioning that a number of biologics manufacturers are presently offering services related to the niche and emerging classes of biologics.

Over 620 partnerships were established in this domain, during the period 2015-2020
Majority of the deals (~24%) recorded in the report, were established in 2020, primarily driven by the investigational biologic drugs against COVID-19. Further, a large number (~35%) of the partnerships were observed to be focused on the manufacturing of biologics, followed by product development and manufacturing agreements (22%).

Currently, the installed biopharmaceutical contract manufacturing capacity is estimated to be ~3.9 million liters, which is gradually being expanded
In order to meet the growing demand for biologics, 177 expansion projects were undertaken by CMOs between 2016 and 2020 Of the aforementioned initiatives, more than 40% were focused on the establishment of new facilities, followed by the expansion of existing manufacturing facilities (24%).

North America and Europe are anticipated to capture 75% share (in terms of service revenues) of the market, by 2030
At present, close to 90% of the total revenues are generated from projects involving commercialized biologic products, and this trend is unlikely to change significantly in the short to mid-term. Further, it is worth mentioning that the contract biomanufacturing market for biologics in the Middle East and North Africa is anticipated to grow at a relatively faster rate (13.6%), followed by the Asia-Pacific market (11.2%).

To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis....

The USD 34.2 billion (by 2030) financial opportunity within the biopharmaceutical contract manufacturing market has been analyzed across the following segments:
 Commonly outsourced business operations
 API
 FDF

 Types of Expression Systems Used
 Mammalian
 Microbial
 Others

 Scale of Operation
 Preclinical / Clinical
 Commercial

 Company Size
 Small
 Mid-sized
 Large / Very Large

 Types of Biologics Manufactured
 Antibody Therapeutics
 Vaccines
 Cell Therapies
 Other Biologics

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific
 Latin America
 Middle East and North Africa

The report includes profiles of key players (listed below) each profile features an overview of the company, information related to its biologics focused service portfolio, manufacturing facilities, recent developments, and an informed future outlook.
 AGC Biologics
 Boehringer Ingelheim
 Catalent
 Cytiva (GE Healthcare)
 FUJIFILM Diosynth Biotechnologies
 KBI Biopharma
 Kemwell Biopharma
 Lonza
 Luina Bio
 Novasep
 Olon
 Patheon
 Piramal Pharma Solutions
 Takara Bio
 WuXi AppTec (WuXi Biologics)

For additional details, please visit
https://www.rootsanalysis.... email salesrootsanalysis.com

You may also be interested in the following titles:
1. Vaccine Contract Manufacturing Market (3rd Edition), 2021-2030
2. ADC Contract Manufacturing Market (4th Edition), 2020-2030
3. Microbial Contract Manufacturing Market, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com

Contact Details
Ben Johnson
+1 (415) 800 3415
ben.johnsonrootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis....
LinkedIn: https://in.linkedin.com/co...
Twitter: https://twitter.com/RootsA...
Medium: https://medium.com/RootsA...
Pinterest: https://in.pinterest.com/R...
Quora: https://rootsanalysisinsig...

Biopharmaceutical Contract Biomanufacturing Market, (4th Edition), 2020-2030
Owing to the complexities associated with the production of biologics, biopharmaceutical developers are likely to continue relying on contract service providers for various aspects of their respective product development programs
London
Roots Analysis has announced the addition of the “Biopharmaceutical Contract Biomanufacturing Market, (4th Edition), 2020-2030” report to its list of offerings.
Given the rising popularity of biologics and the 8,000+ such product candidates under clinical investigation, the opportunity for contract manufacturing service providers engaged in this domain, is high and anticipated to persist in the mid-long term, as well. In fact, since 2000, over 120 new CMOs have been established, offering a variety of cost-efficient manufacturing services and solutions to biologic developers.
To order this 780+ page report, which features 300+ figures and 270+ tables, please visit this - https://www.rootsanalysis....

Key Market Insights
Presently, 225 CMOs, possessing over 380 manufacturing facilities, claim to offer manufacturing services for biopharmaceutical products
The manufacturing services market for biopharmaceuticals is highly fragmented, featuring a mix of small, mid-sized, large and very large players. It is worth mentioning that more than 60% of CMOs mentioned in the report, have the necessary capabilities to manufacture biologics across all scales of operation.

More than 65% of service providers offer manufacturing services for recombinant proteins and peptides
Close to 58% of CMOs claim to have the required capabilities to offer antibody manufacturing services. It is worth mentioning that a number of biologics manufacturers are presently offering services related to the niche and emerging classes of biologics.

Over 620 partnerships were established in this domain, during the period 2015-2020
Majority of the deals (~24%) recorded in the report, were established in 2020, primarily driven by the investigational biologic drugs against COVID-19. Further, a large number (~35%) of the partnerships were observed to be focused on the manufacturing of biologics, followed by product development and manufacturing agreements (22%).

Currently, the installed biopharmaceutical contract manufacturing capacity is estimated to be ~3.9 million liters, which is gradually being expanded
In order to meet the growing demand for biologics, 177 expansion projects were undertaken by CMOs between 2016 and 2020 Of the aforementioned initiatives, more than 40% were focused on the establishment of new facilities, followed by the expansion of existing manufacturing facilities (24%).

North America and Europe are anticipated to capture 75% share (in terms of service revenues) of the market, by 2030
At present, close to 90% of the total revenues are generated from projects involving commercialized biologic products, and this trend is unlikely to change significantly in the short to mid-term. Further, it is worth mentioning that the contract biomanufacturing market for biologics in the Middle East and North Africa is anticipated to grow at a relatively faster rate (13.6%), followed by the Asia-Pacific market (11.2%).

To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis....

Key Questions Answered
 Who are the leading players offering contract manufacturing services for biologics?
 What percentage of the manufacturing operations for biopharmaceutical are presently outsourced?
 What factors should be taken into consideration while deciding whether the manufacturing operations for biologics should be kept in-house or outsourced?
 What is the current, installed capacity for contract manufacturing for biopharmaceuticals?
 What is the current, global demand for biologics and how is it likely to evolve in the foreseen future?
 What are the key (geographical) manufacturing hubs for biologics?
 What kind of partnership models are commonly adopted by stakeholders engaged in this domain?
 What are the different biopharmaceuticals focused initiatives undertaken by big pharma players in the recent past?
 How is the current and future market opportunity likely to be distributed across key market segments?

The USD 34.2 billion (by 2030) financial opportunity within the biopharmaceutical contract manufacturing market has been analyzed across the following segments:
 Commonly outsourced business operations
 API
 FDF

 Types of Expression Systems Used
 Mammalian
 Microbial
 Others

 Scale of Operation
 Preclinical / Clinical
 Commercial

 Company Size
 Small
 Mid-sized
 Large / Very Large

 Types of Biologics Manufactured
 Antibody Therapeutics
 Vaccines
 Cell Therapies
 Other Biologics

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific
 Latin America
 Middle East and North Africa

The report includes profiles of key players (listed below) each profile features an overview of the company, information related to its biologics focused service portfolio, manufacturing facilities, recent developments, and an informed future outlook.
 AGC Biologics
 Boehringer Ingelheim
 Catalent
 Cytiva (GE Healthcare)
 FUJIFILM Diosynth Biotechnologies
 KBI Biopharma
 Kemwell Biopharma
 Lonza
 Luina Bio
 Novasep
 Olon
 Patheon
 Piramal Pharma Solutions
 Takara Bio
 WuXi AppTec (WuXi Biologics)

For additional details, please visit
https://www.rootsanalysis.... email salesrootsanalysis.com

You may also be interested in the following titles:
1. Vaccine Contract Manufacturing Market (3rd Edition), 2021-2030
2. ADC Contract Manufacturing Market (4th Edi

Antibody Contract Manufacturing Market, 2020-2030 by Roots Analysis
With over 100 therapeutic monoclonal antibodies and antibody-based products in the market, the demand for developing and manufacturing of such products is anticipated to increase beyond the capabilities of innovator companies alone

Roots Analysis has announced the addition of the “Antibody Contract Manufacturing Market, 2020-2030” report to its list of offerings.

Although biopharmaceuticals offer significant profit margins and have been proven to be effective in treating a myriad of diseases, they are generally associated with high costs of development and complex manufacturing protocols; this is true for antibody-based products as well. Presently, there are a number of companies that claim to offer end-to-end solutions, ranging from antibody development to commercial production. Further, prevalent trends suggest that sponsor companies are likely to continue relying on contract service providers for various aspects of antibody-based product development and manufacturing.

To order this 285+ page report, which features 100+ figures and 110+ tables, please visit this - https://www.rootsanalysis....

Key Market Insights

Over 100 CMOs presently claim to offer manufacturing services for antibodies
The Antibody Contract manufacturing market is currently dominated by the presence of small and mid-sized companies, which represent 70% of the industry stakeholders. It is also worth highlighting that more than 55% of CMOs claim to have the capabilities to manufacture antibodies across all scales of operation (preclinical, clinical and commercial).

More than 90% service providers are focused on the production of monoclonal antibodies
However, players based in Asia are now increasingly focusing on the development of bispecific antibodies for therapeutic use. It worth highlighting that close to 20% of the CMOs engaged in this domain claim to offer manufacturing services for both bispecific antibodies and antibody fragments.

Europe has emerged as a key manufacturing hub for antibody-based products
More than 120 manufacturing facilities have been established by various players, worldwide; of these, 40% are in Europe. Additionally, 40% of the total installed capacity is in Europe, followed by Asia. Some of the prominent regions in Asia include (in decreasing order of number of manufacturing facilities) China, South Korea, India, Japan and Taiwan.

More than 90 partnership agreements have been inked between 2013 and 2019
Majority of these agreements were focused on manufacturing of various types of antibodies. Other popular types of collaboration models include process development and manufacturing agreements (22%), product development and manufacturing agreements (10%) and licensing agreements (7%).

Multiple expansion initiatives were undertaken by CMOs between 2017 and 2019
More than 50% of such initiatives were reported to be focused on the expansion of manufacturing facilities, followed by building new facilities (38%). It is worth noting that close to 50% of the total number of expansion initiatives were undertaken in Europe, of which, 25% were in the UK.

Demand for therapeutic antibodies is anticipated to grow at a CAGR of 10%, during 2020-2025
Given the fact that there are a number of antibody-based products in the market, the commercial demand for antibodies is significantly higher than the clinical demand. Across the three major global regions, North America represent over half of the overall global manufacturing demand for antibodies.

North America and Europe are anticipated to capture over 70% of the market share by 2030
However, the market in the Asia is anticipated to grow at a relatively faster rate. Further, presently, more than 90% of the antibodies are being developed using mammalian expression systems, and this trend is unlikely to change significantly in short to mid-term.

To request a sample copy / brochure of this report, please visit this- https://www.rootsanalysis....

Key Questions Answered
 Who are the leading CMOs engaged in the production of antibody-based therapeutics?
 What kind of partnership models are commonly adopted by stakeholders in this industry?
 What is the annual clinical and commercial demand for antibody-based products?
 What is the current installed capacity for manufacturing of antibodies?
 What are the various expansion initiatives undertaken by antibody CMOs?
 How is the current and future market opportunity likely to be distributed across key market segments?

The USD 17 billion (by 2030) financial opportunity within the antibody contract manufacturing market has been analyzed across the following segments:
 Type of Antibodies
 Monoclonal Antibodies
 Bispecific Antibodies
 ADCs
 Others

 Company Size
 Small
 Mid-sized
 Large / Very Large

 Scale of Operation
 Preclinical / Clinical
 Commercial

 Type of expression system used
 Mammalian
 Microbial

 Key geographical regions
 North America
 Europe
 Asia and RoW

The report features inputs from eminent industry stakeholders, according to whom antibody therapeutics developers are increasingly outsourcing their manufacturing operations owing to complex nature of the overall process, as well as the high investments associated with setting-up in-house expertise. The report includes detailed transcripts of discussions held with the following experts:
 Dietmar Katinger (Chief Executive Officer, Polymun Scientific)
 David C Cunningham (Director, Corporate Development, Goodwin Biotechnology)
 Claire Otjes (Marketing Manager, Batavia Biosciences)

The research covers profiles of key players that offer manufacturing services for antibodies, featuring a company overview, information on their respective service portfolios, manufacturing facilities and capa

The porphyria therapies market is projected to grow at an annualized rate of 10.97% during the period 2021-2030, claims Roots Analysis
Several novel and innovative therapeutic approaches, both small molecule and biologics, are being currently investigated at various phases of development in order to avoid the beginning of disease-induced attacks and other long-term effects of porphyria

Roots Analysis has announced the addition of “Porphyria Targeting Therapies Market, 2021-2030” report to its list of offerings.

Porphyria is a rare disorder that is characterized by excessive accumulation of porphyrin, a compound that aids in the formation of heme (an essential part of hemoglobin that helps carry oxygen in blood). Any anomaly caused by genetic or acquired abnormalities in heme biosynthesis (produced majorly in bone marrow and liver) can result in toxicity. It is worth highlighting that, till date, more than 1,000 mutations that can cause porphyria have been identified. However, prevalence of porphyria still remains unknown. Several treatment options such as gene therapy, proteasome inhibition and pharmacologic chaperones are currently being investigated among various other targeted treatment options.

To order this 130+ slides report, which features 90+ figures, please visit https://www.rootsanalysis....

Key Market Insights

15+ therapies have been / are being developed for the treatment of different types of porphyria
More than 70% of the aforementioned candidates are currently under clinical evaluation. Further, three therapies, namely Panhematin™, GIVLAARI® and SCENESSE®, have already been approved for the treatment of different types of porphyria.

Around 50% of the therapeutics are being developed as biologics
Majority (over 65%) of the abovementioned biologic drugs have been / are being designed for administration via the intravenous route. Furthermore, majority of the drugs (37%) have been / are being targeting acute intermittent porphyria.

Over 30% of the therapies have been / are being developed for erythropoietic protoporphyria
More than 65% the abovementioned therapies are currently being evaluated in clinical phases. Further, around 60% of the aforementioned therapy candidates are being developed as small molecules.

More than 45% of the players evaluating therapies for porphyria are small companies
North America has emerged as a key hub for the development of porphyria therapies, featuring the presence of 65% developers. The developer landscape is further dominated by players that have been established between 2001-2010, representing around 45% of the total number of stakeholders.

A number of clinical trials evaluating therapies for porphyria, have been registered
Majority of the clinical studies have been completed. More than 30% of the overall trials are phase I studies. Further, it is worth noting that, most of the trials (~ 60%) focused on porphyria therapies were registered post-2010.

Partnership activity in this field has increased at a CAGR of 9.6%, between 2018 and 2020
More than 70% of the reported deals were established post-2018, with the maximum activity being reported in 2019 and 2020. Majority of the instances captured in the report were product distribution / commercialization agreements (~45%).

380+ articles have been published related to porphyria, since January 2018
Close to 20% publications mentioned in the report were focused on the assessment of therapeutics that have been / are being developed for the treatment of erythropoietic protoporphyria. Example of prominent journals include (in decreasing order of number of publications) Molecular Genetics, Orphanet Journal of Rare Diseases, British Journal of Dermatology and Molecular Genetics, and Metabolism Reports.

Around 15 eminent individuals were identified as key opinion leaders (KOLs) in this domain
More than 65% of these KOLs were observed to be associated with organizations based in US, followed by those affiliated to institutes in Spain (20%) and South Africa (7%). Further, over 65% of the KOLs are currently affiliated to academic institutes, such as schools and universities.

North America is anticipated to capture over 60% of the global market share in 2030
In 2030, more than 50% of the market revenues are expected to be generated from sales of therapeutics intended for the treatment of erythropoietic protoporphyria and porphyria cutanea tarda. Further, therapies designed for oral route of administration are expected to occupy a larger share (51%) of the overall market, in the foreseen future.

To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis....

Key Questions Answered
 What are the prevalent R&D trends related to Porphyria?
 What are the key challenges faced by stakeholders engaged in this domain?
 What are the principal therapies developed by the companies in this domain?
 Who are the leading industry and non-industry players in this market?
 What are the key geographies where research on porphyria is actively being conducted?
 Who are the key investors in this domain?
 Who are the key opinion leaders / experts in this field?
 What kind of partnership models are commonly adopted by industry stakeholders?
 What are the factors that are likely to influence the evolution of this upcoming market?
 How is the current and future market opportunity likely to be distributed across key market segments?

The financial opportunity within the porphyria therapies market has been analyzed across the following segments:

 Drug
 GIVLAARI®
 Panhematin®
 SCENESSE®
 MT-7117
 Colestid
 HARVONI®

 Type of Porphyria
 Acute Hepatic Porphyria
 Acute Intermittent Porphyria
 Erythropoietic Protoporphyria
 Hereditary Coproporphyria
 Porphyria Cutanea Tarda
 Variegate Porphyria
 X-Linked Por

The light activated therapies market is anticipated to grow at an annualized rate of 27.7% till 2030, claims Roots Analysis

Light activated therapies are considered to be a transformative approach owing to their capability to eradicate diseased cells from the body with minimal side effects; presenting lucrative opportunities for players engaged in the development of such products

London

Roots Analysis has announced the addition of “Light Activated Therapies Market: Focus on Photodynamic Therapies, Photoimmunotherapies and Photothermal, 2021-2030“ report to its list of offerings.

Rising prevalence of skin disorders is expected to promote the adoption of light activated therapies, making it one of the relatively faster growing segments of this industry. The growing interest of pharmaceutical stakeholders in this field is also reflected from the recent rise in clinical trials registered for such therapy candidates. With multiple therapeutic leads in mid to late development stages (phase II and above), the light activated therapies market is likely to witness significant growth in the foreseen future.

To order this 140+ page report, which features 80+ figures and 120+ tables, please visit https://www.rootsanalysis....

Key Market Insights

More than 125 marketed / under development light activated therapies form the current pipeline
At present, 13% of such therapies are marketed, while majority (82%) of the aforementioned candidates are still being evaluated in clinical phases. Examples of approved therapies include Ameluz®, Foscan®, Hemoporfin®, Metvix®, Photofrin® and Sarotalocan®.

Over 485 clinical trials are currently evaluating light activated therapies, worldwide
It is worth mentioning that most of the trials were / are being conducted in North America (34%). More than 28% patients enrolled in trials conducted in the aforementioned region were recruited across different sites in the United States. Further, 69% of the trials are being sponsored by non-industry players.

Over 635 patents have been filed / granted for light activated therapies, since 2018
Over 35% of these intellectual property documents were filed / granted in the North America, with maximum number of patents being filed in US. This is followed by Europe (33%), Asia Pacific and rest of the world (30%).

By 2030, the opportunity within the light activated therapies market is likely to be dominated by the North America
Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and likely approval of several advanced stage therapy candidates. Further, Europe and North America (primarily the US) are expected to capture over 80% share of the total market (in terms of sales-based revenues), in 2030.

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis....

Key Questions Answered
 What are the prevalent R&D trends related to light activated therapies?
 What are the key therapeutic areas for which light activated therapies have been / are being developed?
 What are the key challenges faced by stakeholders engaged in the manufacturing of light activated therapies?
 Who are the leading industry and non-industry players engaged in the development of light activated therapies?
 Across which geographies, extensive research related to light activated therapies is being conducted?
 Which factors are likely to influence the evolution of this upcoming market?
 How is the current and future market opportunity likely to be distributed across key market segments?

The financial opportunity within the light activated therapies market has been analyzed across the following segments:

 Target Indication
 Head and Neck Cancer
 Actinic Keratosis
 Macular Degeneration,
 Polypoidal Choroidal Vasculopathy
 Cervical Intraepithelial Neoplasia
 Bladder Cancer
 Barrett’s Esophagus
 Gastric Cancer
 Lung Cancer
 Port-Wine Stain
 Others

 Key Players

 Key Geographical Regions
 North America
 Europe
 Asia Pacific

The research includes detailed profiles of key players (listed below); each profile features an overview of the company, its financial information (if available), details on product portfolio and recent developments, as well as an informed future outlook.
 ADVANZ PHARMA
 Biofrontera
 biolitec Pharma
 Luzitin
 Nanospectra Biosciences
 Photoatomic
 Rakuten Medical
 Steba biotech
 Theralase

For additional details, please visit
https://www.rootsanalysis....

You may also be interested in the following titles:
1. Fc Fusion Therapeutics Market: Industry Trends and Global Forecasts, 2020-2030
2. CRISPR Based Therapeutics Market: Industry Trends and Global Forecasts, 2020-2030
3. Cell and Gene Therapy CROs Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030
4. TIL-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
5. TCR-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
6. CAR-T Cell Therapies Market: Industry Trends and Global Forecasts, 2021-2030

Contact Details
Ben Johnson
+1 (415) 800 3415
ben.johnsonrootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis....
LinkedIn: https://in.linkedin.com/co...
Twitter: https://twitter.com/RootsA...
Medium: https://medium.com/RootsA...
Pinterest: https://in.pinterest.com/R...
Quora: https://rootsanalysisinsig...

Hola, este es mi primera publicación, les voy a contar sobre la evolución de la Web:

El avance tecnológico es un proceso continuo. Nada ocurre en un día. Tomemos, por ejemplo, la Revolución Industrial, que abarcó los años 1760 a 1840. Comenzó en el Reino Unido y se extendió por Europa y Estados Unidos. La introducción de la automatización a través de equipos fue el eje de la Revolución Industrial. Antes de esta época todo se hacía a mano. Era la Era de la Máquina.

La evolución de la propia web puede considerarse un reflejo de la Web3 y su interacción con el metaverso. La Web1 fue el sistema que sentó las bases para la creación de estándares que permitieran a un dispositivo enviar otro conjunto de instrucciones. Muchos ordenadores pueden conectarse y seguir estas instrucciones simultáneamente, lo que les permite comunicarse entre sí. Esta técnica permite que un ordenador intercambie un documento o un programa informático con otro, lo que dio lugar a la fundación de Internet. La mayoría de los usuarios de la web1 eran pasivos, incapaces de crear sus contenidos a menos que pudieran crear sus sitios web.
El afán por conseguir más cosas con Internet de las que permitía la web1, como mostrar contenidos producidos por los usuarios y grupos en línea, dio lugar a la web2 y a las empresas comerciales deseosas de llenar los vacíos. La gran tecnología surgió de la demanda de más y más datos y medios para categorizarlos y acceder a ellos, lo que dio lugar al rápido crecimiento de Google y al auge de medios sociales como Facebook. Los individuos pudieron percibirse como usuarios activos en Internet y actores activos en el crecimiento de sus capacidades, gracias a que las empresas que están detrás aceleraron la realidad de la actualización de los deseos humanos.
La desventaja de este avance es que estas empresas han conseguido eficiencia y comodidad utilizando servidores privados. Esto los compara con semidioses que pueden reunir y recuperar datos mientras establecen su propio conjunto de leyes y regulaciones. Todo lo que se sube o se publica en sus sitios se convierte en su propiedad al instante. Tienen un control total sobre el mercado y todo lo que hay en él.
Web3 hace uso de las características descentralizadas de blockchain para crear un ecosistema de anonimato. La persona tiene control y privacidad sobre sí misma y sus posesiones en este entorno. Web3 establece protocolos con blockchain, sentando las bases de un nuevo conjunto de normas y actividades. Blockchain trasciende las fronteras y ayuda a desarrollar un sentimiento de propiedad e identidad digital. Crea un terreno de juego equitativo. Y al hacerlo, establece una base para lo que vendrá.
La frase "el metaverso" se ha definido y reinterpretado varias veces. Aunque se atribuye a Stephenson el establecimiento de un marco para nuestro conocimiento del metaverso, el concepto sigue desarrollándose. En la siguiente sección, hablaremos del significado del metaverso.
Significado del metaverso
No existe una definición ampliamente consensuada de un verdadero metaverso que no sea una versión más elegante de Internet. Los defensores del metaverso, Silicon Valley, citan con frecuencia a Matthew Ball, inversor de riesgo y autor del exhaustivo Metaverse Primer:
El metaverso es una vasta red de mundos y simulaciones 3D persistentes y generados en tiempo real que permiten la identidad, los objetos, la historia, los pagos y los derechos y que pueden ser experimentados simultáneamente por un número prácticamente infinito de usuarios, cada uno con su sensación de presencia.
Facebook, probablemente la mayor empresa tecnológica que participa en el metaverso, lo expresa de forma más sucinta:
El 'metaverso' es una colección de lugares virtuales en los que puedes desarrollarte y explorar con personas que no están físicamente allí contigo.
También hay categorías de metaversos más generales, como la del diseñador de juegos Raph Koster, que distingue entre mundos online, multiversos y metaversos.
Mundos en línea
Según Koster, los mundos en línea son lugares digitales centrados en un único tema central, que van desde sofisticados paisajes en 3D a otros basados en texto.
Los multiversos, como el OASIS de Ready Player One, son muchos mundos distintos conectados en red que no tienen un único tema o reglamento.
Por otro lado, un metaverso es un multiverso que interactúa más con el mundo real, incluyendo superposiciones de realidad aumentada, vestuarios de realidad virtual en tiendas reales e incluso aplicaciones como Google Maps.
Transición de empresas
Por ejemplo, en una conferencia de realidad aumentada y virtual de Facebook Connect en octubre de 2021, Facebook anunció que había cambiado su nombre a Meta.
El cambio de nombre refleja los objetivos de expansión de la empresa más allá de las redes sociales. El nuevo nombre de Facebook, Meta, describe la ambición de la empresa de trabajar y jugar en un entorno virtual.
Además del cambio de nombre, la empresa ha anunciado que su símbolo bursátil pasará de FB a MVRS el 1 de diciembre. Sin embargo, no habrá cambios en el uso de la aplicación de medios sociales. Además, el cambio de nombre no afectará a las otras plataformas de medios sociales como Instagram y Whatsapp.
El cambio de marca podría ser un esfuerzo por restaurar la reputación de Facebook y pasar página tras una serie de desastres de relaciones públicas, como la desinformación en sus plataformas, las infracciones en la moderación de contenidos y las revelaciones sobre el mal impacto de sus productos en la salud mental de algunas personas.

In response Reiino Brasil to his Publication

Aperte a tecla Windows + R (executar)e depois digite tpm.msce pressione Enter. Vai aparecer essa janela abaixo informando se está ativado ou não na BIOS o TPM.

Existem casos, basta apenas ativar pela BIOS.
Reinicie seu Windows/computador e pressione a tecla Delete (Del) ou F2 para entrar na BIOS, geralmente vai encontrar em configurações e depois Intel Platform Trust Technology (PTT).

Importante: não é possível informar de todas as placas mães, cada Marca/Placa Mãe tem um padrão para ativar o TPM. É necessário verificar diretamente com o fabricante.

In response Colibri Mobile to his Publication

unfortunately there's no IOS app.... so I can't comment anything about it...

Please, we need IOS app to test as well...

Nothing found!

Sorry, but we could not find anything in our database for your search query {{search_query}}. Please try again by typing other keywords.